» Lymphoma


MAGNIFY: A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma (NCT01996865)
The purpose of this clinical trial to compare the efficacy and safety of two maintenance regimens following induction therapy.
Website: http://www.clinicaltrials.gov/ct2/show/NCT01996865?term=magnify&rank=1
Principal Investigator: Dr. Ravin Garg
Research Staff:   Emily Ross, CCRC – (443)481-4392
                                      Venita Alston Crawford, RN – (443)481-4393

Our Studies